RPG Life Sciences Reports Strong H1 FY27 Growth and API Expansion
RPG Life Sciences Ltd · Investor Presentation · 30 Oct 2026, 4:54 am
RPG Life Sciences Reports Strong H1 FY27 Growth and API Expansion RPG Life Sciences reported a 16.2% YoY increase in revenue from operations to ₹407.3 cr for H1 FY27, with adjusted EBITDA rising 16.1% YoY to ₹97.9 cr (24.0% margin) and adjusted PAT growing 14.8% YoY to ₹62.9 cr. Segmentally, Domestic Formulations grew 13.0% YoY to ₹278.3 cr, International Formulations rose 7.0% YoY to ₹71.7 cr, and API surged 58.5% YoY to ₹54.6 cr. The company established dedicated subsidiary RPG Active Pharma, partnering with InvAscent with a ₹700 cr capital pool, and acquired Actis and Raghava Life Sciences.
Original exchange filing (PDF)
More announcements from RPG Life Sciences Ltd
- Earning call Transcript · 05 Nov 2026
- Audio Recording of Q2FY27 Results Earnings Call held on October 30, 2026 · 31 Oct 2026
- Amendment to Policy on Related Party Transactions · 30 Oct 2026
- Press Release · 30 Oct 2026
- Outcome of Board Meeting held on October 29, 2026. · 30 Oct 2026
- Financial Result for the quarter ended September 30, 2026 · 30 Oct 2026
- Outcome of Board Meeting · 30 Oct 2026
- Outcome of Board meeting · 30 Oct 2026
